Last updated on: 07/02/2012
Name of organisation
1) Department/Research groupDivision of Clinical Pharmacology
2) Organisation/affiliationKarolinska Institutet
Short Name in the inventoryClinical Pharmacology at Karolinska
Administrative Contact
Title Professor
Last name Dahl
First name Marja-Liisa
Address line 1Division of Clinical Pharmacology
Address line 2Department of Laboratory Medicine
Address line 3Karolinska University Hospital, Huddinge
CityStockholm
PostcodeSE-141 86
CountrySweden
Phone number (incl. country code)46858581059
Alternative phone number
Fax number (incl. country code)46858581070
Scientific Contact
Title Professor
Last name Bergman
First name Ulf
Address line 1Division of Clinical Pharmacology
Address line 2Department of Laboratory Medicine
Address line 3Karolinska University Hospital, Huddinge
CityStockholm
PostcodeSE-141 86
CountrySweden
Phone number (incl. country code)46858581196
Alternative phone number46705554849
Fax number (incl. country code)46858581070
2. Description
Clinical Pharmacology is a medical specialty and a resource in the health care system to support the proper use of drugs. Our Dept. at Karolinska University Hospital provides teaching, research and clinical pharmacology services for Karolinska Institutet and the Stockholm county. We are running a Therapeutic Drug Monitoring laboratory, and a Regional Pharmacovigilance Unit for the Swedish Medical Products Agency. We have an international collaboration including Asia, Africa and WHO. We have integrated pharmacovigilance and pharmacoepidemiology with pharmacogenetics and pharmacokinetics for 40 years now with a focus on the growing and aging population. Recent examples are: Vaccine Vigilance: Safety of pandemic flu vaccine in the population of Stockholm, Sweden (BMJ 2011); PhD theses: Anders Sundström (May 2010) Methods in Pharmacoepidemiology: Four Studies, Four Settings and Anders Helldén (Sept 2010) Aciclovir–induced neuropsychiatric symptoms – a clinical pharmacology study.
3. Category
University based
Hospital based
4. Available resources
In houseVia Contacts/Network
5. Therapeutic/disease areas of research in drug safety/risk-benefit performed in the past 5 years
Cardiovascular diseases
Congenital Malformations
Disorders of the central nervous system
Endocrine disorders
Gastrointestinal tract
Geriatrics
Immunological products and vaccines
Immunosuppression
Infectious diseases
Liver disease
Musculoskeletal and joint diseases
Neonates
Paediatrics
Poisoning/Overdose
Pregnancy
Psychiatry
Renal impairment
Respiratory diseases
Skin disorders
Urinary tract disorders
6. Design of drug safety/risk-benefit studies published in the past 5 years
Cohort Study
Case Control Study
Drug Utilisation
Interventional Clinical Trial
Meta-Analysis
pharmacogenetics
7. Experience in collecting data directly from individual patients/respondents
Number of Studies
Greater than 5
Number of patients/respondents involved in the study(ies)
Less than 150
Between 150 and 1499
8. Access to data collection resources
Capacity to conduct face-to-face interviews
Yes
In a clinic
Yes
In the community
Yes
Electronic data capture systems
Yes
System used:
medical records
Interactive voice response systems
No
Call centre
Yes
9. Experience in secondary research and meta-analysis
Yes
10. Work with existing data resources in the past 3 years
Name of data resourceNo. of studies
Swedish Prescribed Drug Register2
GPRD1
Swedis2
National pregnancy register2
Sfinx interaction database2
11. Registries established by centre
Drug RegistryTherapeutic Drug Monitoring
Disease RegistryDrugs and Pregnancy and Nursing
12. Experience in collaboration in a study team
Principal Investigator
Collaborating Investigator
13. Current involvement in research networks
Other networks:
Network nameNationalInternationalLink to webpage
Eu2P and Eudragene
No
Yes
14. Interest in research opportunities which are funded
By pharmaceutical companies
By charities
By government
By research councils
By EU funding schemes
15. Interest in contract research only if free to publish results
Yes
16. Selected publications of the last 5 calendar years
ReferenceLink to web-publication
1. Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, Persson I, Sundström A, Westerholm B, Rosén M. The new Swedish Prescribed Drug Register – opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16: 726–35
18. Sundström A, Alfredsson L, Sjölin-Forsberg G, Gerdén B, Bergman U, Jokinen J. Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study. BMJ 2010;341: c5812. doi: 10.1136/bmj.c5812
3. Norstedt-Wikner B, Stiller C-O, Bergman U, Asker C, Källén B. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy. Neonatal outcome and congenital malformations. Pharmacoepidemiology and Drug Safety 2007;16:1203-1210.
4. Wettermark B, Pehrsson Å, Juhasz-Haverinen M, Veg A, Edlert M, Törnwall-Bergendahl G, Almkvist H, Godman B, Bergman U. Financial incentives linked to self-assessment of prescribing patterns: a new approach for quality improvement of drug prescribing in primary care. Quality in Primary Care 2009;17:179–89.
5. Bardage C, Persson I, Örtqvist Å, Bergman U, Ludvigsson JF, Granath F. Neurological and autoimmune disorders after pandemic vaccination with a mono-valent adjuvanted influenza A(H1N1)v vaccine (Pandemrix®): a population-based cohort study in Stockholm, Sweden. BMJ 2011;341:c5812 doi:10.1136/bmj.c5812
